Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual) € in Millions				3 Months Ended		4 Months Ended	6 Months Ended
	Jun. 30, 2023 USD ($)	May 10, 2022 USD ($)	Jun. 24, 2020	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 16, 2021 USD ($)	Dec. 16, 2021 EUR (€)	Jul. 08, 2021 shares	Dec. 01, 2020
Revenue from Contract with Customer, Excluding Assessed Tax				$ 837,159	$ 658,553		$ 1,815,211	$ 1,306,980
Upfront Payment Payable										$ 500,000
Deferred License Revenue, Current	$ 176,471			176,471		$ 176,471	176,471		$ 176,471
Deferred License Revenue, Net of Current Portion	88,235			88,235		88,235	88,235		$ 176,471
Cost of Goods and Services Sold				792,944	411,109		1,519,862	815,855
Alphazyme [Member]
Sale of Stock, Percentage of Ownership after Transaction			2.50%
Proceeds from Sale, Maturity and Collection of Investments							1,300,000
ID Biologics Inc [Member]
Investment Owned, Balance, Shares (in shares) | shares												129,661
Investment Owned, Net Assets, Percentage												0.30%
Cost of Goods and Services Sold	0			0
Alphazyme [Member]
Ownership Percentage													1.99%
Research and Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				793,042	$ 614,435		1,726,976	$ 1,148,156
A Global Food Ingredient Company [Member]
Collaborative Arrangement, Payment for Research and Development Agreement		$ 4,100,000
Collaborative Arrangement, Duration Of Agreement (Year)		2 years
A Global Food Ingredient Company [Member] | Research and Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax						226,000	565,000
A Global Food Ingredient Company [Member] | Research and Development [Member] | Purchase Provision Terms [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				113,000			113,000
A Global Food Ingredient Company [Member] | Success Fees [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				65,500			65,500
Janssen Pharmaceutical Companies [Member]
Deferred License Revenue, Current	176,000			176,000		176,000	176,000
Deferred License Revenue, Net of Current Portion	$ 88,000			88,000		$ 88,000	88,000
Deferred License Revenue				44,000			88,000
Janssen Pharmaceutical Companies [Member] | Research and Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax				$ 191,000			$ 380,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total | €											€ 1.6